Following after Ibrance and Verzenio, a third cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor is landing its prescription code in Korean general hospitals.

Pharmaceutical industry sources reported drug committees at eight major general hospitals like Seoul National University Hospital, Seoul Asan Medical Center, National Cancer Center, Korea University Anam Hospital and Konkuk University Hospital have recently cleared Novartis’ Kisqali (ribociclib).

While awaiting Drug Reimbursement Evaluation Committee’s (DREC) nod after passing Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee in last January, Kisqali is preparing for prescription code-in process